Management of Stroke in Patients on Apixaban
Introduction to Apixaban Management
- The American Heart Association and other guideline societies recommend temporarily discontinuing apixaban and timing its resumption based on stroke size, with endovascular thrombectomy as the preferred acute intervention for large vessel occlusions in patients who experience a stroke while on apixaban 1
Thrombolysis and Thrombectomy
- Thrombolysis (rtPA) is generally contraindicated in patients on apixaban if the INR is above 1.7, although standard coagulation tests don't reliably assess apixaban's effect, according to the European Stroke Organization and European Heart Rhythm Association 1
- Endovascular thrombectomy is the preferred first-line treatment for patients with large vessel occlusion who are on apixaban, as supported by European Stroke Organization and European Heart Rhythm Association recommendations 1
- The safety of administering thrombolytic therapy to patients on direct oral anticoagulants (DOACs) like apixaban is not established, and no antidote availability makes bleeding risk management more challenging, as stated by the American Heart Association/American Stroke Association (AHA/ASA) and the European Heart Rhythm Association (EHRA) 2, 3
- Laboratory assessment limitations: standard coagulation tests do not reliably assess the anticoagulant effect of apixaban, making it difficult to determine if thrombolysis can be safely administered, according to the American Heart Association/American Stroke Association (AHA/ASA) 2
- If the time of last apixaban dose is unknown or within 48 hours, it is recommended to assume the patient is anticoagulated, and thrombolysis may only be considered if apixaban levels are <30 ng/mL (measured at least 4 hours after last dose), based on expert consensus from the European Heart Rhythm Association (EHRA) 3
Resuming Apixaban
- For patients with a large stroke or stroke with hemorrhagic transformation, the European Heart Rhythm Association recommends delaying resumption of apixaban for 14 days after stroke onset 1
- Consider repeat brain imaging before restarting anticoagulation in patients with large stroke or stroke with hemorrhagic transformation, as suggested by the European Society of Cardiology 4
- The timing of resuming apixaban depends on stroke size, with specific guidelines for Transient Ischemic Attack (TIA), small-sized stroke, medium-sized stroke, and large stroke, according to the European Stroke Organization 1
Bridging and Anticoagulation
- There is generally no need for bridging with heparin or LMWH when restarting apixaban, according to the European Society of Anaesthesiology 5
- In very high thrombotic risk patients, individualized bridging decisions may be needed, as recommended by the European Society of Cardiology 5
Medication Management
- If stroke occurs despite proper adherence to apixaban, consider switching to another anticoagulant, as suggested by the European Society of Cardiology 4
- Avoid combination therapy of apixaban with antiplatelet agents for long-term stroke prevention, as this significantly increases bleeding risk without clear benefit, according to the American Heart Association 1
Risk Factor Management
- Consider adding antiplatelet therapy only in specific situations (e.g., recent coronary stenting), as combination therapy increases bleeding risk, as recommended by the American College of Cardiology 1
- Regular assessment of renal function is necessary, as apixaban dosing depends partly on renal function, according to the European Renal Association 5
- Evaluate for and manage vascular risk factors (hypertension, diabetes, hyperlipidemia) to reduce the risk of recurrent stroke, as recommended by the European Society of Cardiology 4
- Apixaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation, as recommended by the European Heart Rhythm Association (EHRA) and other guideline societies, highlighting the importance of weighing the benefits and risks of anticoagulation therapy in different clinical contexts 6, 7